Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Viruses Turbo-Charge Bacterial Evolution in Cystic Fibrosis Infections

By University of Liverpool | July 5, 2016

Scientists in the U.K. have found new evidence that tiny viruses called bacteriophages turbo-charge the evolution of bacteria that cause lung infections in Cystic Fibrosis patients.

Cystic Fibrosis (CF) patients suffer from life-long lung infections caused by the environmental bacterium Pseudomonas aeruginosa. These infections worsen patient health and limit life-expectancy. Over the years of the infection, the bacteria evolve to become better adapted to the lung environment, becoming very difficult to treat.

Tracking evolutionary change

A team of scientists from the Universities of Liverpool, Salford and York evolved populations of the bacterium P. aeruginosa with or without bacteriophages in a growth medium designed to replicate the sputum in CF lungs. They then tracked evolutionary change in the bacterium using genome sequencing.

The study, published in the Proceedings of the National Academy of Sciences, reports that bacteria with bacteriophages evolved faster to adapt to life in sputum. This happened because the bacteriophage jumped into the bacterium’s DNA, increasing the number of useful mutations that natural selection could use.

Many of the mutations seen in the lab-evolved bacteria, including those caused by the bacteriophage, are also commonly seen in bacteria isolated from CF infections. Because bacteriophages live wherever you find bacteria, including in the lungs of CF patients, this could mean that bacteriophages play an important role in bacterial evolution in the clinic.

Antibiotic threat

Chloe James, Ph.D., a lecturer in Medical Microbiology at the University of Salford, said: “We knew from our previous work that the bacteriophages infecting P. aeruginosa were commonly found in CF patient sputum. We now know that these bacteriophages can speed up evolution helping bacteria adapt to living in a sputum-like environment”

Professor Craig Winstanley, from the University of Liverpool’s Institute of Infection and Global Health, said: “Because some antibiotics can activate bacteriophages, some antibiotic therapies might help bacteria to adapt to the lung faster making the infections even more difficult to treat.”

Prof. Michael Brockhurst, of the University of York, added: “To design better treatments and preserve our antibiotics we urgently need to better understand how bacteria evolve in infections. These new results suggest that bacteriophages may play a much bigger role than previously thought, by turbo-charging evolutionary adaptation.”

 

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE